Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

201 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and Efficacy of Apitegromab in Patients With Spinal Muscular Atrophy Types 2 and 3: The Phase 2 TOPAZ Study.
Crawford TO, Darras BT, Day JW, Dunaway Young S, Duong T, Nelson LL, Barrett D, Song G, Bilic S, Cote S, Sadanowicz M, Iarrobino R, Xu TJ, O'Neil J, Rossello J, Place A, Kertesz N, Nomikos G, Chyung Y. Crawford TO, et al. Among authors: nomikos g. Neurology. 2024 Mar 12;102(5):e209151. doi: 10.1212/WNL.0000000000209151. Epub 2024 Feb 8. Neurology. 2024. PMID: 38330285 Free PMC article. Clinical Trial.
A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular Atrophy.
Barrett D, Bilic S, Chyung Y, Cote SM, Iarrobino R, Kacena K, Kalra A, Long K, Nomikos G, Place A, Still JG, Vrishabhendra L. Barrett D, et al. Among authors: nomikos g. Adv Ther. 2021 Jun;38(6):3203-3222. doi: 10.1007/s12325-021-01757-z. Epub 2021 May 8. Adv Ther. 2021. PMID: 33963971 Free PMC article. Clinical Trial.
Patient phenotyping in clinical trials of chronic pain treatments: IMMPACT recommendations.
Edwards RR, Dworkin RH, Turk DC, Angst MS, Dionne R, Freeman R, Hansson P, Haroutounian S, Arendt-Nielsen L, Attal N, Baron R, Brell J, Bujanover S, Burke LB, Carr D, Chappell AS, Cowan P, Etropolski M, Fillingim RB, Gewandter JS, Katz NP, Kopecky EA, Markman JD, Nomikos G, Porter L, Rappaport BA, Rice ASC, Scavone JM, Scholz J, Simon LS, Smith SM, Tobias J, Tockarshewsky T, Veasley C, Versavel M, Wasan AD, Wen W, Yarnitsky D. Edwards RR, et al. Among authors: nomikos g. Pain. 2016 Sep;157(9):1851-1871. doi: 10.1097/j.pain.0000000000000602. Pain. 2016. PMID: 27152687 Free PMC article. Review.
Effects of vortioxetine on functional capacity across different levels of functional impairment in patients with major depressive disorder: a University of California, San Diego Performance-based Skills Assessment (UPSA) analysis.
Jacobson W, Zhong W, Nomikos GG, Christensen MC, Kurre Olsen C, Harvey PD. Jacobson W, et al. Among authors: nomikos gg. Curr Med Res Opin. 2020 Jan;36(1):117-124. doi: 10.1080/03007995.2019.1657692. Epub 2019 Aug 29. Curr Med Res Opin. 2020. PMID: 31422713 Clinical Trial.
Suicidal ideation and behavior in adults with major depressive disorder treated with vortioxetine: post hoc pooled analyses of randomized, placebo-controlled, short-term and open-label, long-term extension trials.
Mahableshwarkar AR, Affinito J, Reines EH, Xu J, Nomikos G, Jacobsen PL. Mahableshwarkar AR, et al. Among authors: nomikos g. CNS Spectr. 2020 Jun;25(3):352-362. doi: 10.1017/S109285291900097X. Epub 2019 Jun 14. CNS Spectr. 2020. PMID: 31199210 Clinical Trial.
201 results